(Reuters) – The first people vaccinated with an experimental Ebola shot being developed by Merck and NewLink have had no serious side effects so far, but a few experienced mild fever, Swiss researchers said on Tuesday.
The shot, one of several being fast-tracked through clinical trials in the hope they can be approved for use in the Ebola epidemic raging in West Africa, is undergoing initial human safety tests at the University Hospitals of Geneva… (read more)
Leave a Reply